Latest Earnings Results: Q2 '26
Estimated EPS
-$0.03
Reported EPS
-$0.03
Surprise
-5.88%
Estimated Rev
$1.84M
Reported Rev
$1.07M
Surprise
-41.97%
Lineage Cell Therapeutics reported total revenue of $1.1 million for the three months ended June 30, 2026, and $2.8 million for the six months ended June 30, 2026, respectively.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | -$0.03 | -- | -- | N/A |
Q2 '26 | -$0.03 | -$0.03 | -5.88% | MISSED |
Q1 '26 | -$0.02 | -$0.03 | -50.00% | MISSED |
Q4 '25 | -$0.04 | $0.00 | 109.33% | BEAT |
Q3 '25 | -$0.03 | -$0.13 | -405.56% | MISSED |